Skye Bioscience Inc (SKYED)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
METAL MINING
CEO:
Brian S. Murphy
Employees:
9
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
(858) 410-0266

Skye Bioscience, Inc. discovers, develops, and commercializes cannabinoid-based molecules. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.

Data derived from most recent annual or quarterly report
Market Cap 1.11 Million Shares Outstanding12.339 Million Avg 30-day Volume 134.347 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.58
Price to Revenue0.0 Debt to Equity-0.0116 EBITDA-18.877 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value20.227 Million
Current Ratio0.193 EPS Growth-0.5 Quick Ratio0.056
1 Yr BETA 1.0872 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-40.0105 Free Cash Flow to Firm (FCFF) TTM -5.271 Million Free Cash Flow to Equity (FCFE) TTM-11.821 Million
Altman Z-Score-78.2912
View SEC Filings from SKYED instead.

View recent insider trading info

Skye Bioscience Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SKYED (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SKYED

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-06 by WARD KEITH WAYNE
  • 4: filed on 2023-11-06 by CHARYCH DEBORAH H.
  • 4: filed on 2023-11-06 by ARSENAULT KAITLYN
  • 4: filed on 2023-11-06 by DHILLON PUNIT
  • 4: filed on 2023-11-06 by DALESANDRO MARGARET
  • 4: filed on 2023-11-06 by GRAYSON PAUL A.
  • 4: filed on 2023-11-06 by TYLE PRAVEEN
  • 4: filed on 2023-11-06 by SCHWAB ANDREW J.
  • 4: filed on 2023-08-29 by SCHWAB ANDREW J.
  • 4: filed on 2023-08-29 by GRAYSON PAUL A.

    • Events (8k)

  • 8-K: filed on 2023-11-07:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-07:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2023-08-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-08-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2023-03-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DALESANDRO MARGARET

    • Director
    		 0 2023-11-06 3

    TYLE PRAVEEN

    • Director
    		 0 2023-11-06 4

    DHILLON PUNIT CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 297,006 2023-11-06 3

    SCHWAB ANDREW J.

    • Director
    		 0 2023-11-06 4

    WARD KEITH WAYNE

    • Director
    		 0 2023-11-06 3

    GRAYSON PAUL A.

    • Director
    		 246,252 2023-11-06 3

    ARSENAULT KAITLYN CHIEF FINANCIAL OFFICER

    • Officer
    		 185,738 2023-11-06 2

    CHARYCH DEBORAH H.

    • Director
    		 0 2023-11-06 5

    5AM PARTNERS VII, LLC

    5AM VENTURES VII, L.P.

    5AM PARTNERS II, LLC

    5AM VENTURES II LP

    5AM CO-INVESTORS II LP

    DIEKMAN JOHN D

    PARMAR KUSH

    ROCKLAGE SCOTT M

    • 10% Owner
    		 1,130,857,157 2023-08-18 1

    VERSANT VENTURES III, LLC

    VERSANT VENTURE CAPITAL III, L.P.

    VERSANT SIDE FUND III, L.P.

    • 10% Owner
    		 501,925,802 2023-08-18 1

    RAI SUKHWINDER SINGH

    • Director
    		 250,000 2023-01-05 1

    EMERALD HEALTH SCIENCES INC.

    • 10% Owner
    		 169,407,901 2022-11-10 0

    HEPPELL JAMES L

    • Director
    		 1,350,000 2021-09-14 0

    JANNEY RICHARD PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2020-09-25 0

    KIM DENNIS D CHIEF MEDICAL OFFICER

    • Officer
    		 4,736,541 2020-08-07 0

    TRAISTARU ELENA CFO AND SECRETARY

    • Officer
    		 1,000,000 2020-08-07 0

    DHILLON AVTAR S

    • Director
    		 0 2018-10-10 0

    CESARIO DOUGLAS A CFO AND SECRETARY

    • Officer
    		 643,501 2018-07-23 0

    LYKOS COSMAS N CHAIRMAN

    • Officer
    • Director
    • 10% Owner
    		 4,599,400 2018-01-18 0

    BERECZ ELIZABETH CHIEF FINANCIAL OFFICER

    • Officer
    		 1,050,000 2018-01-18 0

    MURPHY BRIAN STUART CEO, CHIEF MEDICAL OFFICER

    • Officer
    • Director
    		 1,275,000 2018-01-18 0

    LAPHAM REG ALEXANDER

    • 10% Owner
    		 3,787,500 2017-03-13 0

    INGRAM DOUGLAS S VICE CHAIRMAN

    • Officer
    • Director
    		 372,500 2015-10-20 0

    GEORGE THOMAS

    • Director
    		 60,000 2015-10-20 0

    MCLAUGHLIN GERALD W.

    • Director
    		 61,250 2015-10-20 0

    LADIN BRIAN D

    • 10% Owner
    		 249,098 2015-04-08 0

    SQUIRES RICHARD D.

    • 10% Owner
    		 1,500,000 2015-04-03 0

    HOLLISTER JOHN B CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2014-12-04 0

    MENDEZ YOSBANI

    • FORMER OFFICER, DIRECTOR, 10%
    		 No longer subject to file 2014-10-31 0

    MENDEZ FRANCISCO JAVIER

    • FORMER OFFICER AND DIRECTOR
    		 No longer subject to file 2014-10-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SCHWAB ANDREW J. - Director

    		2023-11-06 20:29:02 -0500 2023-11-06 A 14,110 a 20,001 direct

    TYLE PRAVEEN - Director

    		2023-11-06 20:29:14 -0500 2023-11-06 A 14,110 a 20,001 direct

    GRAYSON PAUL A. - Director

    		2023-11-06 20:29:25 -0500 2023-11-06 A 173,721 a 246,252 direct

    DALESANDRO MARGARET - Director

    		2023-11-06 20:29:36 -0500 2023-11-06 A 14,110 a 20,001 direct

    DHILLON PUNIT - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-11-06 20:29:48 -0500 2023-11-06 A 21,586 a 30,599 direct

    DHILLON PUNIT - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-11-06 20:29:48 -0500 2023-11-06 A 194,270 a 297,006 direct

    ARSENAULT KAITLYN - Officer CHIEF FINANCIAL OFFICER

    		2023-11-06 20:29:59 -0500 2023-11-06 A 32,053 a 45,436 direct

    ARSENAULT KAITLYN - Officer CHIEF FINANCIAL OFFICER

    		2023-11-06 20:29:59 -0500 2023-11-06 A 128,209 a 185,738 direct

    CHARYCH DEBORAH H. - Director

    		2023-11-06 20:30:10 -0500 2023-11-06 A 14,110 a 20,001 direct

    WARD KEITH WAYNE - Director

    		2023-11-06 20:32:26 -0500 2023-11-06 A 14,110 a 20,001 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SKYE BIOSCIENCE INC SKYED 2023-10-10 22:15:04 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 21:45:04 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 21:15:04 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 20:45:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 20:15:04 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 19:45:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 19:15:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 18:45:04 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 18:15:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 17:45:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 17:15:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 16:45:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 16:15:03 UTC -20.332 25.652 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 15:45:04 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 15:15:04 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 14:45:03 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 14:15:04 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 13:45:04 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 13:15:04 UTC -38.9081 44.2281 50000
    SKYE BIOSCIENCE INC SKYED 2023-10-10 12:45:04 UTC -38.9081 44.2281 50000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments